2-furoyl-ligrlo-amide|CAS 729589-58-6|DC Chemicals

Cas No.:	729589-58-6
Chemical Name:	2-Furoyl-LIGRLO-amide
Synonyms:	2-(2-FUROYL)-LEU-ILE-GLY-ARG-LEU-ORN-NH2;PAR-2 AGONIST II;PROTEINASE ACTIVATED RECEPTOR-2 AGONIST II;2-(2-FUROYL)-LIGRLOAMIDE;2-(2-FUROYL)-PAR-2 (2-6)-ORN AMIDE (MOUSE, RAT);2F-LIGRLO-AMIDE;2-FUROYL-LEU-ILE-GLY-ARG-LEU-ORN-NH2;2-FUROYL-LIGRLO-AMIDE;(2-Furoyl)-PAR-2 (2-6)-Orn amide (mouse, rat);2-(2-Furoyl)-PAR-2 (2-6)-Orn amide (mouse, rat) ,2-(2-Furoyl)-LIGRLOamide;2-furoyl-LIGRLO amide;HY-P1314;MS-31409;BDBM50412718;729589-58-6;PD019049;N-[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1-[[(2S)-1,5-diamino-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]furan-2-carboxamide;AKOS024457384;CHEMBL509819;CS-0029361;GLXC-25026;G13493;fur-2-oyl-Leu-Ile-Gly-Arg-Leu-Orn-NH2
SMILES:	CC[C@@H]([C@H](NC([C@@H](NC(C1=CC=CO1)=O)CC(C)C)=O)C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CCCN)=O)CC(C)C)=O)CCCNC(N)=N)=O)=O)C
Formula:	C₃₆H₆₃N₁₁O₈
M.Wt:	777.95400
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.